VEGFA and nonpapillary renal cell carcinoma: For a treatment naïve, ECOG 0 ccRCC patient with “favorable” risk per IMDC, who is determined to need systemic therapy and has no contraindication to receiving either an IO or an anti-VEGF therapy, 50% of the subcommittee recommend treatment with axitinib/pembrolizumab, 28% recommend treatment with nivolumab/ipilimumab, 11% recommend TKI monotherapy, and 6% recommend treatment with either axitinib/avelumab or HDIL-2.